The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions

Current Allergy and Asthma Reports

Volumn 16, Issue 4, 2016, Pages 1-19

  Yee, Christina S K ^a   Rachid, Rima ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Desensitization; Food allergy; Oral immunotherapy; Sustained unresponsiveness

Indexed keywords

ALLERGEN; OMALIZUMAB;

CLINICAL TRIAL (TOPIC); DESENSITIZATION; FOOD HYPERSENSITIVITY; HUMAN; ORAL DRUG ADMINISTRATION; PROCEDURES; TRENDS;

ADMINISTRATION, ORAL; ALLERGENS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; FOOD HYPERSENSITIVITY; HUMANS; OMALIZUMAB;

EID: 84959338673     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-016-0602-0     Document Type: Review

References (91)

1. Gupta RS et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128(1):e9–17.
2. Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics. 2009;124(6):1549–55.
3. Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133(2):291–307. quiz 308.
4. Liu AH et al. National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005–2006. J Allergy Clin Immunol. 2010;126(4):798–806. e13.
5. Rona RJ et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol. 2007;120(3):638–46.
6. Host A. Clinical course of cow’s milk protein allergy and intolerance. Pediatr Allergy Immunol. 1998;9(11 Suppl):48–52.
7. Host A et al. Clinical course of cow’s milk protein allergy/intolerance and atopic diseases in childhood. Pediatr Allergy Immunol. 2002;13 Suppl 15:23–8.
8. Savage JH et al. The natural history of egg allergy. J Allergy Clin Immunol. 2007;120(6):1413–7.
9. Hourihane JO, Roberts SA, Warner JO. Resolution of peanut allergy: case-control study. BMJ. 1998;316(7140):1271–5.
10. Skolnick HS et al. The natural history of peanut allergy. J Allergy Clin Immunol. 2001;107(2):367–74.
11. Fleischer DM et al. The natural history of tree nut allergy. J Allergy Clin Immunol. 2005;116(5):1087–93.
12. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107(1):191–3.
13. Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001–2006. J Allergy Clin Immunol. 2007;119(4):1016–8.
14. Muraro A et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy. 2014;69(8):1008–25.
15. Panel NI-SE et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(6 Suppl):S1–58.
16. Muraro A et al. EAACI food allergy and anaphylaxis guidelines: managing patients with food allergy in the community. Allergy. 2014;69(8):1046–57.
17. Sampson HA et al. Food allergy: a practice parameter update—2014. J Allergy Clin Immunol. 2014;134(5):1016–25. e43.
18. Cummings AJ et al. The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy. 2010;65(8):933–45.
19. Lieberman JA, Sicherer SH. Quality of life in food allergy. Curr Opin Allergy Clin Immunol. 2011;11(3):236–42.
20. van der Velde JL, Dubois AE, Flokstra-de Blok BM. Food allergy and quality of life: what have we learned? Curr Allergy Asthma Rep. 2013;13(6):651–61.
21. Anagnostou K et al. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy. 2011;41(9):1273–81.
22. Blumchen K et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126(1):83–91. e1.
23. Clark AT et al. Successful oral tolerance induction in severe peanut allergy. Allergy. 2009;64(8):1218–20.
24. Jones SM et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124(2):292–300. 300 e1–97.
25. Narisety SD et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–82. e1–6.
26. Patriarca G et al. Oral rush desensitization in peanut allergy: a case report. Dig Dis Sci. 2006;51(3):471–3.
27. Varshney P et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654–60. First double-blind, placebo-controlled RCT of peanut OIT.
28. Keet CA et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129(2):448–55. 455 e1–5.
29. Longo G et al. Specific oral tolerance induction in children with very severe cow’s milk-induced reactions. J Allergy Clin Immunol. 2008;121(2):343–7.
30. Meglio P et al. A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. Allergy. 2004;59(9):980–7.
31. Skripak JM et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2008;122(6):1154–60.
32. Buchanan AD et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119(1):199–205.
33. Caminiti L et al. Oral immunotherapy for egg allergy: a double-blind placebo-controlled study, with postdesensitization follow-up. J Allergy Clin Immunol. 2015;3(4):532–9.
34. Dello Iacono I et al. Specific oral tolerance induction with raw hen’s egg in children with very severe egg allergy: a randomized controlled trial. Pediatr Allergy Immunol. 2013;24(1):66–74.
35. Fuentes-Aparicio V et al. Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergol Immunopathol. 2013;41(3):143–50.
36. Garcia Rodriguez R et al. Oral rush desensitization to egg: efficacy and safety. Clin Exp Allergy. 2011;41(9):1289–96.
37. Itoh N, Itagaki Y, Kurihara K. Rush specific oral tolerance induction in school-age children with severe egg allergy: one year follow up. Allergol Int. 2010;59(1):43–51.
38. Letran A et al. Threshold doses in specific oral tolerance induction in children with egg allergy. J Investig Allergol Clin Immunol. 2012;22(2):147–9.
39. Meglio P et al. Oral food desensitization in children with IgE-mediated hen’s egg allergy: a new protocol with raw hen’s egg. Pediatr Allergy Immunol. 2013;24(1):75–83.
40. Morisset M et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow’s milk allergy and 90 children with egg allergy. Eur Ann Allergy Clin Immunol. 2007;39(1):12–9.
41. Ojeda P et al. Home-based oral immunotherapy protocol with pasteurized egg for children allergic to hen’s egg. Isr Med Assoc J. 2012;14(1):34–9.
42. Patriarca G et al. Oral specific desensitization in food-allergic children. Dig Dis Sci. 2007;52(7):1662–72.
43. Ruiz Garcia M et al. Commercial dehydrated egg white for specific oral tolerance induction (SOTI): an easier treatment for egg allergy. J Investig Allergol Clin Immunol. 2012;22(7):529–31.
44. Staden U et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy. 2007;62(11):1261–9.
45. Tortajada-Girbes M et al. Specific oral tolerance induction (SOTI) to egg: our experience with 19 children. J Investig Allergol Clin Immunol. 2012;22(1):75–7.
46. Vazquez-Ortiz M et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg-allergic children. Clin Exp Allergy. 2014;44(1):130–41.
47. Vickery BP et al. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010;105(6):444–50.
48. Pacharn P et al. Successful wheat-specific oral immunotherapy in highly sensitive individuals with a novel multirush/maintenance regimen. Asia Pac Allergy. 2014;4(3):180–3.
49. Rodriguez del Rio P et al. Oral immunotherapy in children with IgE-mediated wheat allergy: outcome and molecular changes. J Investig Allergol Clin Immunol. 2014;24(4):240–8.
50. Sato S et al. Wheat oral immunotherapy for wheat-induced anaphylaxis. J Allergy Clin Immunol. 2015;136(4):1131–3. e7.
51. Begin P, Chinthrajah RS, Nadeau KC. Oral immunotherapy for the treatment of food allergy. Hum Vaccin Immunother. 2014;10(8):2295–302.
52. Begin P et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014;10(1):1.
53. Hofmann AM et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124(2):286–91. 291 e1–6.
54. Vickery BP et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133(2):468–75. Long-term study of sustained unresponsiveness in peanut OIT trial.
55. Anagnostou K et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014;383(9925):1297–304. Large-scale RCT for peanut OIT.
56. Syed A et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133(2):500–10.
57. Bird JA, Spergel J, Jones SM, Rachid R, Assa’ad AH, Wang J, Leonard SA, Laubach SS, Kim EH, Vickery BP, Davis B, Heimall J, Cinaferoni A, MacGinnitie AJ, Crestani E, Elfont RM, Sampson HA, Burks AW. A novel characterized peanut allergen formulation (AR101) for oral immunotherapy (OIT) induces desensitization in peanut-allergic subjects: a phase 2 clinical safety and efficacy study, in EAACI 2015. Barcelona, Spain; 2015.
58. Schneider LC et al. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368–74.
59. Burton OT et al. Oral immunotherapy induces IgG antibodies that act through FcgammaRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014;134(6):1310–7. e6.
60. Tang ML et al. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol. 2015;135(3):737–44. e8.
61. Meglio P et al. Oral desensitization in children with immunoglobulin E-mediated cow’s milk allergy—follow-up at 4 yr and 8 months. Pediatr Allergy Immunol. 2008;19(5):412–9.
62. Narisety SD et al. Open-label maintenance after milk oral immunotherapy for IgE-mediated cow’s milk allergy. J Allergy Clin Immunol. 2009;124(3):610–2.
63. Keet CA et al. Long-term follow-up of oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2013;132(3):737–739 e6. Long term evaluation of outcomes for milk OIT.
64. Caminiti L et al. A new protocol for specific oral tolerance induction in children with IgE-mediated cow’s milk allergy. Allergy Asthma Proc. 2009;30(4):443–8.
65. Pajno GB et al. Oral immunotherapy for cow’s milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol. 2010;105(5):376–81.
66. Pajno GB et al. Comparison between two maintenance feeding regimens after successful cow’s milk oral desensitization. Pediatr Allergy Immunol. 2013;24(4):376–81.
67. Martorell A et al. Oral desensitization as a useful treatment in 2-year-old children with cow’s milk allergy. Clin Exp Allergy. 2011;41(9):1297–304.
68. Salmivesi S et al. Milk oral immunotherapy is effective in school-aged children. Acta Paediatr. 2013;102(2):172–6.
69. Paassilta M et al. Children who were treated with oral immunotherapy for cows’ milk allergy showed long-term desensitisation seven years later. Acta Paediatr. 2016;105(2):215–9. Placebo-controlled RCT of milk OIT with long-term follow-up.
70. Nadeau KC et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127(6):1622–4.
71. Wood RA, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2015. Double-blinded, placebo-controlled RCT of omalizumab as adjunct to milk OIT.
72. Goldberg MR et al. Efficacy of baked milk oral immunotherapy in baked milk-reactive allergic patients. J Allergy Clin Immunol. 2015;136(6):1601–6.
73. Burks AW, Jones SM. Egg oral immunotherapy in non-anaphylactic children with egg allergy: follow-up. J Allergy Clin Immunol. 2008;121(1):270–1.
74. Burks AW et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233–43. Large-scale, double-blind, placebo-controlled RCT for egg OIT.
75. Escudero C et al. Early sustained unresponsiveness after short-course egg oral immunotherapy: a randomized controlled study in egg-allergic children. Clin Exp Allergy. 2015;45(12):1833–43.
76. Leonard SA et al. Dietary baked egg accelerates resolution of egg allergy in children. J Allergy Clin Immunol. 2012;130(2):473–80. e1.
77. Begin P et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol. 2014;10(1):7.
78. Henson, M., et al., Peanut oral immunotherapy and omalizmab treatment for peanut allergy. J Allergy Clin Immunol. 2012; 6749:S0091(11):11.
79. Takahashi M et al. New efficacy of LTRAs (montelukast sodium): it possibly prevents food-induced abdominal symptoms during oral immunotherapy. Allergy Asthma Clin Immunol. 2014;10(1):3.
80. Mansfield L. Successful oral desensitization for systemic peanut allergy. Ann Allergy Asthma Immunol. 2006;97(2):266–7.
81. Bird JA, Spergel J, Jones SM, Rachid R, Assa’ad AH, Wang J, Leonard SA, Laubach SS, Kim EH, Vickery BP, Davis B, Heimall J, Cinaferoni A, MacGinnitie AJ, Crestani E, Elfont RM, Sampson HA, Burks AW. A novel characterized peanut allergen formulation (AR101) for oral immunotherapy (OIT) induces desensitization in peanut-allergic subjects: a phase 2 clinical safety and efficacy study, in EAACI. Barcelona, Spain; 2015.
82. Leung DY et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348(11):986–93.
83. Hospital BCs, et al. Peanut reactivity reduced by oral tolerance in an anti-ige clinical trial (PRROTECT). 2013–2016.01.17; Available from: https://clinicaltrials.gov/ct2/show/NCT01781637?term=01781637.
84. Patriarca C et al. Oral specific hyposensitization in the management of patients allergic to food. Allergol Immunopathol. 1984;12(4):275–81.
85. Yeung JP et al. Oral immunotherapy for milk allergy. Cochrane Database Syst Rev. 2012;11, CD009542.
86. Ibanez MD et al. Comprehensive review of current knowledge on egg oral immunotherapy. J Investig Allergol Clin Immunol. 2015;25(5):316–28. Quiz 2 p following 328; Comprehensive review of egg OIT clinical studies.
87. Romantsik O et al. Oral and sublingual immunotherapy for egg allergy. Cochrane Database Syst Rev. 2014;11, CD010638. Meta-analysis of recent egg OIT RCT.
88. Rachid R, Umetsu DT. Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol. 2012;34(5):689–702. Review of mechanisms of tolerance in OIT.
89. Arasi S et al. Two year effects of food allergen immunotherapy on quality of life in caregivers of children with food allergies. Allergy Asthma Clin Immunol. 2014;10(1):57.
90. Lebovidge JS et al. Assessment of psychological distress among children and adolescents with food allergy. J Allergy Clin Immunol. 2009;124(6):1282–8.
91. Otani IM et al. Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects. Allergy Asthma Clin Immunol. 2014;10(1):25.